Eisai Inc.
Global Headquarters:
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088 Japan
US Headquarters: 100 Tice Blvd.
Woodcliff Lake
New Jersey
07677
United States
335 articles with Eisai Inc.
-
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
-
Eisai to Present Latest DAYVIGO® (lemborexant) CIV Data at 35th Annual Virtual SLEEP 2021 Meeting
6/9/2021
Eisai Inc. announced today new presentations featuring the latest data about the company's insomnia medication DAYVIGO will be presented at the 35th annual SLEEP 2021 meeting of the Associated Professional Sleep Societies, LLC (APSS).
-
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.
-
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
-
The U.S. Food and Drug Administration granted approval of Biogen’s aducanumab for the treatment of Alzheimer’s disease.
-
Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™
6/7/2021
Collaborations with Veterans Health Administration, CVS Health and NAFC focused on health disparities in underserved communities
-
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
-
Alzheimer’s patients and their families wait with hope that this will mean some offer of treatment, while physicians that treat Alzheimer’s patients are mulling the implications of the drug, often with hesitancy and skepticism.
-
Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy
5/18/2021
- Data include landmark median progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in patients, including those with triple-negative breast cancer (TNBC)
-
Eisai Data at ASCO 2021 Highlight Breadth of Oncology Portfolio Across Various Tumor Types
5/17/2021
Eisai to present more than 25 abstracts including investigational data on oncology pipeline and products Oral presentations include two trials from the LEAP (Lenvatinib And Pembrolizumab) clinical program evaluating the combination in patients with advanced renal cell carcinoma and advanced melanoma
-
Epilepsy Foundation Collaborates with Eisai to Develop Epilepsy Digital Experience Navigator
5/4/2021
the Epilepsy Foundation announced a collaboration with Eisai Inc. to develop a new platform — the Epilepsy Digital Experience Navigator — designed to empower people with epilepsy, their caregivers, and clinicians to use data to better understand and improve the epilepsy journey.
-
Eisai Announces Publication of Post Hoc Analysis Data of LENVIMA® (lenvatinib) from Phase 3 SELECT Trial in Certain Patients with Differentiated Thyroid Cancer in the European Journal of Cancer
4/29/2021
Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival (OS) in patients with locally recurrent or metastatic, progressive radioiodine-refractory differentiated thyroid cancer
-
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy
4/20/2021
Eisai Co., Ltd. and Biogen Inc. announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimer's Research and Therapy.
-
Eisai And Advocacy Leaders Team Up To Launch Spot Her - An Initiative That Empowers Women To Help Spot The Signs Of Endometrial Cancer
3/31/2021
Eisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health and the health of other women first.
-
One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
KEYTRUDA® Plus LENVIMA® Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
3/19/2021
KEYTRUDA Plus LENVIMA Significantly Reduced the Risk of Death by 38%, With a Median Overall Survival of 18.3 Months Versus 11.4 Months With Chemotherapy Regardless of Mismatch Repair Status
-
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021
3/15/2021
BioArctic AB announced data on the drug candidate lecanemab, which were presented by the company and its partner Eisai at the 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD™.
-
Eisai to Present Investigational Data from Oncology Pipeline at the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer
3/10/2021
Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer
-
Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually.